Search clinical trials for: JNJ-38431055

Total 1080 results

Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

Influenza A Virus

Belgium
Janssen Pharmaceutical K.K.

Terminated

A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

Dermatitis, Atopic

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

Alzheimer Disease

Spain, Netherlands, Belgium, Sweden
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Atopic Dermatitis

United States
Janssen Vaccines & Prevention B.V.
Bavarian Nordic

Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections

United States, Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Low Back Pain | Low Back Pain, Recurrent

United States, Belgium, Canada, Netherlands
Janssen Research & Development, LLC
City of Hope Medical Center

Recruiting

A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Taiwan, Poland, United Kingdom, Georgia, Ukraine, Moldova, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis (FRONTIER 2)

Plaque Psoriasis

United States, Korea, Republic of, Germany, France, Taiwan, Japan, Spain, United Kingdom, Poland, Canada
Janssen Research & Development, LLC

Completed

A Study of JNJ-64281802 in Healthy Adult Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States, Spain
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989 in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

No longer available

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma

Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.

Neoplasms | Lymphoma

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Alzheimer's Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants

Healthy

Belgium
Bausch Health Americas, Inc.

Completed

A Study of a New Drug Treatment for Acne

Acne Vulgaris

United States
Janssen Research & Development, LLC

Withdrawn

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Healthy

United States
Janssen Sciences Ireland UC

Completed

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (REEF-1)

Hepatitis B, Chronic

Belgium, United States, Japan, Korea, Republic of, France, Hong Kong, Canada, Italy, Thailand, Germany, Malaysia, Spain, Russian Federation, Turkey, United Kingdom, Poland, Brazil, Czechia, China
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-75276617 in Participants With Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemias

United States, United Kingdom, France, Spain, Australia
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, Israel, Japan, Germany, Spain, Australia, China, France, United Kingdom, Greece, Italy
Janssen Research & Development, LLC

Completed

A Study of JNJ-63733657 in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989 in Adult Participants With Renal Impairment

Renal Impairment

Germany
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

Renal Impairment

Germany
Janssen Research & Development, LLC

Completed

A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

Hepatic Impairment

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech, Inc.

Terminated

A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.

Neoplasms
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

Advanced Prostate Cancer

United States, France
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

Healthy
Janssen R&D Ireland

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Chronic Hepatitis C Infection

Taiwan
Janssen Research & Development, LLC

Withdrawn

A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Active Rheumatoid Arthritis; Rheumatoid Arthritis
Janssen Pharmaceutical K.K.

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

Advanced Stage Solid Tumors

Spain
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

Prostatic Neoplasms

United States, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)

Multiple Myeloma

United States, Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Neoplasms

Canada, Israel, Spain
Janssen Research & Development, LLC

Completed

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

Neoplasms

United States, Canada
Janssen Sciences Ireland UC

No longer available

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

Respiratory Syncytial Virus
Janssen Research & Development, LLC

Completed

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

Healthy

United States
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Obesity

United States

3

Subscribe